University of Minnesota Medical School, Minneapolis, MN, United States.
Cincinnati Children's Hospital, Cincinnati, OH, United States.
Pancreatology. 2018 Apr;18(3):286-290. doi: 10.1016/j.pan.2018.02.001. Epub 2018 Feb 6.
BACKGROUND/OBJECTIVES: Total pancreatectomy with islet autotransplantation (TPIAT) is considered for managing chronic pancreatitis in selected patients when medical and endoscopic interventions have not provided adequate relief from debilitating pain. Although more centers are performing TPIAT, we lack large, multi-center studies to guide decisions about selecting candidates for and timing of TPIAT.
Multiple centers across the United States (9 to date) performing TPIAT are prospectively enrolling patients undergoing TPIAT for chronic pancreatitis into the Prospective Observational Study of TPIAT (POST), a NIDDK funded study with a goal of accruing 450 TPIAT recipients. Baseline data include participant phenotype, pancreatitis history, and medical/psychological comorbidities from medical records, participant interview, and participant self-report (Medical Outcomes Survey Short Form-12, EQ-5D, andPROMIS inventories for pain interference, depression, and anxiety). Outcome measures are collected to at least 1 year after TPIAT, including the same participant questionnaires, visual analog pain scale, pain interference scores, opioid requirements, insulin requirements, islet graft function, and hemoglobin A1c. Health resource utilization data are collected for a cost-effectiveness analysis. Biorepository specimens including urine, serum/plasma, genetic material (saliva and blood), and pancreas tissue are collected for future study.
This ongoing multicenter research study will enroll and follow TPIAT recipients, aiming to evaluate patient selection and timing for TPIAT to optimize pain relief, quality of life, and diabetes outcomes, and to measure the procedure's cost-effectiveness. A biorepository is also established for future ancillary studies.
背景/目的:全胰切除术伴胰岛自体移植术(TPIAT)被认为是治疗慢性胰腺炎的一种方法,适用于那些经过药物和内镜治疗后仍无法缓解严重疼痛的患者。尽管越来越多的中心正在开展 TPIAT,但我们缺乏大型多中心研究来指导选择 TPIAT 候选患者和手术时机的决策。
美国多个中心(目前有 9 个中心)正在前瞻性地招募接受 TPIAT 治疗慢性胰腺炎的患者进入 TPIAT 前瞻性观察研究(POST),这是一项由 NIDDK 资助的研究,目标是招募 450 名 TPIAT 接受者。基线数据包括参与者表型、胰腺炎病史以及从病历、参与者访谈和参与者自我报告中获取的医疗/心理合并症信息(医疗结局研究短式 12 项健康调查量表、EQ-5D 和 PROMIS 疼痛干扰、抑郁和焦虑量表)。在 TPIAT 后至少 1 年收集结局测量数据,包括相同的参与者问卷、视觉模拟疼痛量表、疼痛干扰评分、阿片类药物需求、胰岛素需求、胰岛移植物功能和糖化血红蛋白 A1c。收集健康资源利用数据进行成本效益分析。还收集生物库标本,包括尿液、血清/血浆、遗传物质(唾液和血液)和胰腺组织,用于未来的研究。
这项正在进行的多中心研究将招募和随访 TPIAT 接受者,旨在评估 TPIAT 的患者选择和时机,以优化疼痛缓解、生活质量和糖尿病结局,并衡量该手术的成本效益。还建立了一个生物库,用于未来的辅助研究。